US Food and Drug Administration approval of esketamine and brexanolone
Abstract
In March 2019, The USFood and Drug Administration (FDA) approved twonew antidepressants -esketamine for treatment-resistant depression (TRD)1and brexanolone for postpartum depression (PPD).
Domains
Life Sciences [q-bio]
Fichier principal
Cristea_et al_2019_US FDA approval of esketamine_accepted.pdf (1.51 Mo)
Télécharger le fichier
Origin : Files produced by the author(s)
Loading...